Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Expanded inherited metabolic disease (IMD) portfolio; New programs address citrullinemia type 1, phenylketonuria (PKU), and Wilson disease Expect to file INDs for lead IMD product candidates,...
-
CAMBRIDGE, Mass., May 07, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies...
-
Therapeutic Programs Address Citrullinemia Type 1, Phenylketonuria, and Wilson Disease Diseases Can Have Devastating Consequences for Patients and Families, with Few Effective Treatment Options ...
-
Findings Demonstrated Dose-Dependent Durable Gene Expression, and No Apparent Safety Issues Across the Dose Range Tested Topline Data from First Cohort in Phase 1/2 Trial of DTX101 Expected in the...
-
CAMBRIDGE, Mass., April 28, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
-
CAMBRIDGE, Mass., April 18, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
-
CAMBRIDGE, Mass., April 06, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
-
- Treated first patients in phase I/II clinical study of DTX101 for hemophilia B - - Expect to file an IND and initiate dosing for DTX301 for OTC deficiency in second half 2016 - - Selected...
-
CAMBRIDGE, Mass., March 17, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, liver-directed treatments for diverse rare diseases...
-
CAMBRIDGE, Mass., March 01, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, liver-directed treatments for diverse rare diseases...